Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the ...

Bipartisan legislation under review in Congress has the potential to significantly rejigger global drug development — and the biggest beneficiaries may not be American. The bill, titled the Biotech ...

Was molecular biologist David Sabatini a manipulative mentor who coerced a younger colleague into sex? Or was he the victim ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

As I prepared for my appointment, the hospital asked me to sign its registration forms and to sign up for MyChart. In the ...

At the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another Theranos.

The XBI is still up 24%, although it’s down 11% from the August high. The retreat doesn’t look that alarming relative to the ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

U.S. health officials are moving ahead with a plan to allow specialty pharmacies to produce certain peptides, a class of ...

White House planned shift of research funding from universities to industry risks creating a drought in basic research, ...

Ahead of "You Can See Everything" hitting theaters, let's rewind the last decade and review some of the most significant news ...

A jury awarded $6 million in damages to scientist David Sabatini, whose career imploded after he was accused by a much younger colleague of inappropriate sexual conduct in his lab.